연구동향 분석
박사

Study on osteoclast-targeting mechanisms of heterocycles as a potential therapeutic agent for bone-related diseases : 잠재적 골질환 치료제로서 heterocycles의 파골세포 분화 및 활성 억제기전에 관한 연구

인혜정 2015년

논문상세정보
인용/피인용
' Study on osteoclast-targeting mechanisms of heterocycles as a potential therapeutic agent for bone-related diseases : 잠재적 골질환 치료제로서 heterocycles의 파골세포 분화 및 활성 억제기전에 관한 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • bone loss
  • bone resorption
  • kp-a021
  • kp-a159
  • osteoclast
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
129 0

0.0%

' Study on osteoclast-targeting mechanisms of heterocycles as a potential therapeutic agent for bone-related diseases : 잠재적 골질환 치료제로서 heterocycles의 파골세포 분화 및 활성 억제기전에 관한 연구' 의 참고문헌

  • Zhou CH, Wang Y (2012) Recent researches in triazole compounds as medicinal drugs. Curr Med Chem 19:239-80
  • Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K, Oike Y, Takeya M, Toyama Y and Suda T (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202:345-51
  • YAGI, M., MIYAMOTO, T., SAWATANI, Y., IWAMOTO, K., HOSOGANE, N., FUJITA, N.,MORITA, K., NINOMIYA, K., SUZUKI, T., MIYAMOTO, K., OIKE, Y., TAKEYA,M., TOYAMA, Y. & SUDA, T. 2005. DC-STAMP is essential for cell-cell fusion inosteoclasts and foreign body giant cells. J Exp Med, 202, 345-51.
  • Wilson SR, Peters C, Saftig P, Bromme D (2009) Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 284:2584-92
  • Wat WZ (2014) Current perspectives on bisphosphonate treatment in Paget's disease of bone. Ther Clin Risk Manag 20;10:977-83
  • Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24:33-63
  • Walczynski K, Zuiderveld OP and Timmerman H (2005) Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists. Eur J Med Chem 40:15-23
  • Wagner EF and Eferl R (2005) Fos/AP-1 proteins in bone and the immune system. Immunol Rev 208
  • Villa A, Guerrini MM, Cassani B, Pangrazio A, Sobacchi C (2009) Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif Tissue Int 84:1-12
  • Vang T, Xie Y, Liu WH, Vidovi? D, Liu Y, Wu S, Smith DH, Rinderspacher A, Chung C, Gong G, Mustelin T, Landry DW, Rickert RC, Schurer SC, Deng SX, Tautz L (2011) Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids. J Med Chem 54:562-71
  • Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-49
  • Teitelbaum SL and Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-49
  • Teitelbaum SL (2011) The osteoclast and its unique cytoskeleton. Ann N Y Acad Sci 1240:14-7
  • Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504-8
  • Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289(5484):1504-8
  • Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T and Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901
  • Takahashi N, Ejiri S, Yanagisawa S, Ozawa H (2007) Regulation of osteoclast polarization. Odontology 95:1-9
  • Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-57
  • Soysa NS, Alles N, Aoki K, Ohya K (2012) Osteoclast formation and differentiation: an overview. J Med Dent Sci 59:65-74
  • Shi F, Li C, Xia M, Miao K, Zhao Y, Tu S, Zheng W, Zhang G and Ma N (2009) Green chemoselective synthesis of thiazolo[3,2-a]pyridine derivatives and evaluation of their antioxidant and cytotoxic activities. Bioorg Med Chem Lett 19:5565-8
  • Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79
  • Sharma RN, Xavier FP, Vasu KK, Chaturvedi SC and Pancholi SS (2009) Synthesis of 4-benzyl-1,3-thiazole derivatives as potential anti-inflammatory agents: an analogue-based drug design approach. J Enzyme Inhib Med Chem 24:890-7
  • Schneider TL, Shen B and Walsh CT (2003) Oxidase domains in epothilone and bleomycin biosynthesis: thiazoline to thiazole oxidation during chain elongation. Biochemistry 42:9722-30
  • Ruggiero SL, Mehrotra B, Rosenberg TJ and Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-34
  • Rao AU, Palani A, Chen X, Huang Y, Aslanian RG, West RE, Jr., Williams SM, Wu RL, Hwa J, Sondey C and Lachowicz J (2009) Synthesis and structure-activity relationships of 2-(1,4'-bipiperidin-1'-yl)thiazolopyridine as H3 receptor antagonists. Bioorg Med Chem Lett 19:6176-80
  • Ralston SH, Layfield R (2012) Pathogenesis of Paget disease of bone. Calcif Tissue Int 91:97-113
  • Ralston SH and Layfield R (2012) Pathogenesis of Paget disease of bone. Calcif Tissue Int 91:97-113
  • Rachner TD, Khosla S and Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276-87
  • Qin YJ, Wang PF, Makawana JA, Wang ZC, Wang ZN, Yan G, Jiang AQ and Zhu HL (2014) Design, synthesis and biological evaluation of metronidazole-thiazole derivatives as antibacterial inhibitors. Bioorg Med Chem Lett 24(22):5279-83
  • Park-Min KH, Ji JD, Antoniv T, Reid AC, Silver RB, Humphrey MB, Nakamura M, Ivashkiv LB (2009) IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J Immunol 183:2444-55
  • Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK (2009) A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem Biophys Res Commun 378:645-9
  • Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY and Park EK (2009) A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem Biophys Res Commun 378:645-9
  • Park HR, Kim J, Kim T, Jo S, Yeom M, Moon B, Choo IH, Lee J, Lim EJ, Park KD, Min SJ, Nam G, Keum G, Lee CJ and Choo H (2013) Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease. Bioorg Med Chem 21:5480-7
  • Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8:96-110
  • Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T and Isoe T (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 5:2634-43
  • Nijweide PJ, Burger EH, Feyen JH (1986) Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol Rev 66:855-86
  • Ngai MH, Yang PY, Liu K, Shen Y, Wenk MR, Yao SQ, Lear MJ (2010) Click-based synthesis and proteomic profiling of lipstatin analogues. Chem Commun (Camb) 46:8335-7
  • Nakashima T, Takayanagi H (2009) Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 29:555-67
  • Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R (2004) Src kinase activity is essential for osteoclast function. J Biol Chem 279:17660-6
  • Miyamoto T (2006) The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity. Mod Rheumatol 16:341-2
  • Melton LJ 3rd (2000) Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res15:2309-14
  • Marx RE (2008) Uncovering the cause of "phossy jaw" Circa 1858 to 1906: oral and maxillofacial surgery closed case files-case closed. J Oral Maxillofac Surg 66:2356-63
  • Lyles KW, Siris ES, Singer FR, Meunier PJ (2001) A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 16:1379-87
  • Lee T, Lee D, Lee IY and Gong YD (2010) Solid-phase synthesis of thiazolo[4,5-b]pyridine derivatives using Friedlander reaction. J Comb Chem 12:95-9
  • Lee MS, Kim HS, Yeon JT, Choi SW, Chun CH, Kwak HB, Oh J (2009) GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway. J Immunol 183:3390-9
  • Kumar D, Reddy VB, Kumar A, Mandal D, Tiwari R, Parang K (2011) Click chemistry inspired one-pot synthesis of 1,4-disubstituted 1,2,3-triazoles and their Src kinase inhibitory activity. Bioorg Med Chem Lett 21:449-5214. Cronin S, Chandrasekar PH (2010) Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 65:410-6
  • Kumar D, Reddy VB, Kumar A, Mandal D, Tiwari R, Parang K (2011) Click chemistry inspired one-pot synthesis of 1,4-disubstituted 1,2,3-triazoles and their Src kinase inhibitory activity. Bioorg Med Chem Lett 21:449-52
  • Kim HH, Chung WJ, Lee SW, Chung PJ, You JW, Kwon HJ, Tanaka S, Lee ZH (2003) Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation. Exp Cell Res 289:368-77
  • Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-91
  • Kharb R, Sharma PC, Yar MS (2011) Pharmacological significance of triazole scaffold. J Enzyme Inhib Med Chem 26:1-21
  • Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A and Yoneda T (2004) Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114:475-84
  • Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K (2002) U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277:47366-72
  • Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA (2004) The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 279:13984-92
  • He Y, Staser K, Rhodes SD, Liu Y, Wu X, Park SJ, Yuan J, Yang X, Li X, Jiang L, Chen S, Yang FC (2011) Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One 6:e24780
  • He Y, Staser K, Rhodes SD, Liu Y, Wu X, Park SJ, Yuan J, Yang X, Li X, Jiang L, Chen S and Yang FC (2011) Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One 6:e24780
  • Hamade E, Habib A, Hachem A, Hussein AH, Abbas M, Hirz T, Al Masri M and Faour WH (2012) Biological and anti-inflammatory evaluation of two thiazole compounds in RAW cell line: potential cyclooxygenase-2 specific inhibitors. Med Chem 8:401-8
  • Gong YD, Min KH, Lee T (2011) An Efficient Solid-Phase Synthesis of α-1,2,3-Triazoloamide Derivatives via Click Chemistry. Bull Korean Chem Soc 32:2453-6
  • Golob AL, Laya MB (2015) Osteoporosis: Screening, Prevention, and Management. Med Clin North Am 99:587-606
  • Ghayor C, Correro RM, Lange K, Karfeld-Sulzer LS, Gratz KW and Weber FE (2011) Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone. J Biol Chem 286:24458-66
  • Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-49
  • Frodin M and Gammeltoft S (1999) Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 151:65-77
  • Feng X, McDonald JM (2011) Disorders of bone remodeling. Annu Rev Pathol 6:121-45
  • Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL (2003) c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 111:749-58
  • Faccio R, Takeshita S, Zallone A, Ross FP and Teitelbaum SL (2003) c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 111:749-58
  • Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL (1990) Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res 5:311-9
  • Darnay BG, Haridas V, Ni J, Moore PA and Aggarwal BB (1998) Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem 273:20551-5
  • Buckle DR, Rockell CJ, Smith H, Spicer BA (1986) Studies on 1,2,3-triazoles. 13. (Piperazinylalkoxy) [1]benzopyrano[2,3-d]-1,2,3-triazol-9(1H)-ones with combined H1-antihistamine and mast cell stabilizing properties. J Med Chem 29:2262-7
  • Boyle WJ, Simonet WS and Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-42
  • Body JJ (2002) Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 30:75S-79S
  • Bernabei R, Martone AM, Ortolani E, Landi F, Marzetti E (2014) Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab11:201-7
  • BOYLE, W. J., SIMONET, W. S. & LACEY, D. L. 2003. Osteoclast differentiation andactivation. Nature, 423, 337-42.
  • Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251-64
  • Asagiri M and Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251-64
  • Ang E, Liu Q, Qi M, Liu HG, Yang X, Chen H, Zheng MH and Xu J (2011) Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-kappaB and ERK. J Cell Biochem 112:89-97
  • Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR and Glimcher LH (2008) NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118:3775-89
  • ASAGIRI, M., SATO, K., USAMI, T., OCHI, S., NISHINA, H., YOSHIDA, H., MORITA, I.,WAGNER, E. F., MAK, T. W., SERFLING, E. & TAKAYANAGI, H. 2005.Autoamplification of NFATc1 expression determines its essential role in bonehomeostasis. J Exp Med, 202, 1261-9.